Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AZN | London | GBP | Real-time | |
3LAZ | London | GBP | Real-time | |
3SAZ | London | GBP | Real-time | |
AZNl | BATS Europe | GBP | Delayed | |
AZNs | BATS Europe | SEK | Delayed | |
AZN | NASDAQ | USD | Real-time | |
AZNCF | OTC Markets | USD | Delayed | |
AZNN | BIVA | MXN | Delayed | |
AZNN | Mexico | MXN | Delayed | |
AZN | Stockholm | SEK | Real-time | |
AZNPy | Frankfurt | EUR | Delayed | |
AZN | Frankfurt | EUR | Delayed | |
AZN | TradeGate | EUR | Delayed | |
AZN | Xetra | EUR | Delayed | |
AZN | Buenos Aires | ARS | Delayed | |
AZNA | Vienna | EUR | Real-time |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Sell | Neutral | Buy | Buy | Buy |
Technical Indicators | Strong Sell | Strong Sell | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Sell | Sell | Strong Buy | Strong Buy | Strong Buy |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Three Outside Up | 1M | Current | |||
Completed Patterns | |||||
Bullish Engulfing | 1M | 1 | Mar 24 | ||
Engulfing Bearish | 5H | 6 | Apr 23, 2024 07:00AM | ||
Dark Cloud Cover | 15 | 7 | Apr 25, 2024 11:15AM |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
London | 12,000.0 | 11,996.0 | 12,000.0 | 242,861 | -0.23% | GBP | 04:43:39 | ||
London | 4,315.00 | 4,259.00 | 4,333.00 | 0 | 0.00% | GBP | 25/04 | ||
London | 1,648.75 | 1,639.00 | 1,668.00 | 0 | 0.00% | GBP | 25/04 | ||
BATS Europe | 11,990.0 | 11,986.0 | 11,992.0 | 43,491 | -0.15% | GBP | 04:28:27 | ||
BATS Europe | 1,646.50 | 1,636.50 | 1,655.50 | 75 | +10.19% | SEK | 03:01:07 | ||
NASDAQ | 75.03 | 0.00 | 0.00 | 15,120,361 | +5.38% | USD | 25/04 | ||
OTC Markets | 146.055 | 0.000 | 0.000 | 9,266 | +7.91% | USD | 25/04 | ||
BIVA | 1,278.22 | 0.00 | 0.00 | 0 | -0.90% | MXN | 26/05 | ||
Mexico | 1,294.72 | 1,280.01 | 1,315.00 | 19 | +6.68% | MXN | 25/04 | ||
Stockholm | 1,638.5 | 1,637.5 | 1,638.5 | 86,370 | -0.18% | SEK | 04:42:38 | ||
Frankfurt | 70.000 | 69.500 | 70.500 | 0 | +5.26% | EUR | 02:13:52 | ||
Frankfurt | 140.00 | 140.00 | 140.40 | 200 | -0.60% | EUR | 03:00:31 | ||
TradeGate | 140.45 | 140.05 | 140.25 | 814 | +0.43% | EUR | 04:16:18 | ||
Xetra | 140.550 | 140.050 | 140.250 | 7,347 | -0.43% | EUR | 04:09:07 | ||
Buenos Aires | 40,744.000 | 40,575.000 | 40,744.000 | 1,385 | +8.65% | ARS | 25/04 | ||
Vienna | 60.50 | 60.00 | 62.50 | 0 | 0.00% | EUR | 28/02 |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Meta Platforms | 441.38 | 445.77 | 414.50 | -52.12 | -10.56% | 81.83M | 25/04 | ||
Microsoft | 399.04 | 399.89 | 388.04 | -10.02 | -2.45% | 34.49M | 25/04 | ||
Alphabet A | 156.00 | 156.49 | 150.87 | -3.13 | -1.97% | 44.95M | 25/04 | ||
NVIDIA | 826.32 | 833.23 | 782.23 | +29.55 | +3.71% | 40.15M | 25/04 | ||
Snap | 11.40 | 11.55 | 10.54 | +0.32 | +2.89% | 56.65M | 25/04 | ||
Intel | 35.11 | 35.29 | 34.50 | +0.61 | +1.77% | 55.91M | 25/04 | ||
Alphabet C | 157.95 | 158.28 | 152.77 | -3.15 | -1.96% | 31.55M | 25/04 | ||
Amazon.com | 173.67 | 173.92 | 166.37 | -2.92 | -1.65% | 43.43M | 25/04 | ||
Apple | 169.89 | 170.61 | 168.15 | +0.87 | +0.51% | 47.93M | 25/04 | ||
Tesla | 170.18 | 170.88 | 158.36 | +8.05 | +4.97% | 123.18M | 25/04 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review